ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021
Correction to: Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk.
Hans-Peter Hartung et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.